Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa and paclitaxel in recurrent/metastatic gastric cancer
NCT04835896Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of bintrafusp alfa in gastric cancer (GC), sponsored by Yonsei University. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Started Jun 2021; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04835896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835896.